Molecular Characterization
of the Resistance of Mycobacterium tuberculosis
to Second Line Drugs in Côte d’Ivoire
T Ouassa1*, YG
Loukou1, A Dotia1 and H Faye-Kette2
1Department of Bacteriology
and Virology, Faculty of Pharmaceutical and Biological
Sciences. University Félix Houphouët-Boigny, BP V34
Abidjan, Côte d’Ivoire, 2Department of
Bacteriology and Virology, Faculty of Medical Sciences.
University Félix Houphouët-Boigny, BP V34 Abidjan, Côte
d’Ivoire.
*For correspondence:
Email:
timouassa@yahoo.fr;
Tel: +225 02 50 00 78; Fax:
+225 21 25 92 06
Received: 14 June 2013
Revised accepted: 12 March 2014
Tropical
Journal of Pharmaceutical Research, May 2014;
13(5): 727-730
Abstract
Purpose:
To characterize the
resistance of
Mycobacterium tuberculosis to second line drugs
using a line probe assay.
Methods: Multi-drug
resistant strains of
Mycobacterium tuberculosis
isolated between
December 2008 and December
2009 were
tested for resistance to
fluoroquinolones and
second-line injectable
drugs using
GenoType®
MTBDRsl.
Results: Thirty eight strains gave
interpretable results. None of them had a mutation in
the gyrA gene. Regarding
second-line
injectable drugs, 4
strains (11 %) were resistant to aminoglycosides/
capreomycin and all of them harbored A1401G mutation.
Conclusion: No extensive drug resistant
strains were observed.
A relatively high proportion of
strains were resistant to at
least one second-line
injectable
drug. Resistance mechanism
seemed similar for all of them.
Keywords: Mycobacterium tuberculosis,
Line probe assay, GenoType® MTBDRsl,
Aminoglycosides Capreomycin, Mutation
